LUND,
Sweden, April 14, 2022 /PRNewswire/
-- Immunovia, Inc., the American subsidiary of Immunovia AB
(Nasdaq Stockholm: IMMNOV), has submitted an application for a
Current Procedural Terminology (CPT) Proprietary Laboratory
Analyses (PLA) code to the American Medical Association (AMA) for
the IMMray PanCan-d test.
A PLA code for IMMray PanCan-d would allow health care
professionals to specifically identify IMMray PanCan-d when
submitting information and claims to health insurances and
payers.
The PLA submission by Immunovia will be reviewed and voted on by
the Technical Advisor Group on May
13th during a panel meeting. If approved, the
issued PLA code would be published on July
1, 2022, and would be effective on October 1, 2022.
The CPT codes offer doctors and health care professionals a
uniform language for coding medical services and procedures. It is
the most widely accepted medical nomenclature used in the US to
report physician and healthcare professional services including
laboratory tests under public and private health insurance
programs.
PLA Codes are an addition to the CPT code set approved by the
AMA CPT Editorial Panel. They are alpha-numeric CPT codes with a
corresponding descriptor for laboratories or manufacturers that
want to identify their test more specifically.
For more information, please contact:
Philipp Mathieu
Acting CEO and President
Email: philipp.mathieu@immunovia.com
Tobias Bülow
Senior Director Investor Relations and Corporate Communications
Email: tobias.bulow@immunovia.com
Tel: +46 736 36 35 74
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 08:45 CET
April 14, 2022.
About Immunovia
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in which
IMMray™ PanCan-d is commercially available, is the world's largest
market for the detection of pancreatic cancer with an estimated
value of more than USD 4 billion
annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-cpt-pla-code-submission-for-the-immray--pancan-d-test-is-on-the-agenda-of-american-medical,c3546474
The following files are available for download:
https://mb.cision.com/Main/13121/3546474/1564399.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/immunovia-cpt-pla-code-submission-for-the-immray-pancan-d-test-is-on-the-agenda-of-american-medical-association-301525607.html
SOURCE Immunovia AB